Spironolactone Tablet, Film Coated
Product Images NDC 50090-3747

4 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 50090-3747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500903747)

Label Image (Lbl500903747)
Label for Spironolactone 25 mg film-coated tablets by A-S Medication Solutions. The label indicates oral route with 100 tablets per package. Storage instructions specify 68 to 77 degrees Fahrenheit and protection from light. The label also includes the product NDC 50090-3747-0 and dosage information.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A line graph showing probability over time in months comparing Spironolactone and Placebo groups. The graph includes sample sizes for each group (spironolactone n=822, placebo n=841) and indicates a log-rank p-value of less than 0.001, suggesting a statistical comparison between the two groups' outcomes over 48 months.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot displaying hazard ratios (HR) with 95% confidence intervals for various subgroups related to spironolactone treatment effectiveness compared to placebo. Subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACEI use, and beta blocker use. The number of participants and percentages per subgroup are also shown.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure diagram of spironolactone, showing the molecular arrangement including ketone functional groups and methyl substituents. The image depicts the detailed connectivity of atoms in the spironolactone molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.